Abacavir pharmacogenetics - From initial reports to standard of care

Pharmacotherapy

Volumn 33, Issue 7, 2013, Pages 765-775

  Martin, Michael A ^a   Kroetz, Deanna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abacavir; AIDS; Drug hypersensitivity; Genetic testing; HIV; HLA; Pharmacogenetics

Indexed keywords

ABACAVIR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; PLACEBO;

ABDOMINAL PAIN; ALLERGIC REACTION; APPLICATION SITE PRURITUS; BLISTER; CLINICAL PRACTICE; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE QUALITY; HETEROZYGOTE; HLA A GENE; HLA C GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN LEUKOCYTE ANTIGEN B GENE; MALAISE; NAUSEA; PAIN; PHARMACOGENETICS; PHARYNGITIS; PRESCRIPTION; RASH; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INDURATION; SKIN REDNESS; SYMPTOMATOLOGY; VOMITING;

ABACAVIR; AIDS; DRUG HYPERSENSITIVITY; GENETIC TESTING; HIV; HLA; PHARMACOGENETICS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS; REVERSE TRANSCRIPTASE INHIBITORS; STANDARD OF CARE;

EID: 84883192385     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1278     Document Type: Review

References (56)

1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23:1603-14.
2. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999;13:999-1000.
3. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32.
4. Mallal S, Phillips E, Carosi G, et al. HLA-B 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
5. ViiV Healthcare. Epzicom [package insert]. Research Triangle Park, NC; 2012.
6. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999;13:1419.
7. Shear NH, Milpied B, Bruynzeel DP, Phillips EJ. A review of drug patch testing and implications for HIV clinicians. AIDS 2008;22:999-1007.
8. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B 5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008;46:1111-8.
9. Giorgini S, Martinelli C, Tognetti L, et al. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients. Dermatol Ther 2011;24:591-4.
10. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008;47:351-71.
11. Faletto MB, Miller WH, Garvey EP,St Clair MH, Daluge SM, Good SS. Unique intracellular activation of the potent antihuman immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997;41:1099-107.
12. McDowell JA, Chittick GE, Ravitch JR, Polk RE, Kerkering TM, Stein DS. Pharmacokinetics of [14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999;43:2855-61.
13. McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000;44:1686-90.
14. Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron 2001;89:62-7.
15. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40:1559-85.
16. Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 2005;207:145-57.
17. Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet 2009;54:15-39.
18. Hurley CK, Baxter Lowe LA, Logan B, et al.National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 2003;9:610-5.
19. Thomas GP, Brown MA. Genetics and genomics of ankylosing spondylitis. Immunol Rev 2010;233:162-80.
20. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012;44:291-6.
21. Hung SI, Chung WH, Liou LB, et al. HLA-B 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-9.
22. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
23. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-9.
24. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 2012;91:734-8.
25. Feng ML, Guo XJ, Zhang JY, et al. Study on the haplotypes of MICA and MICB microsatellite and HLA-B locus in the Guangzhou Han population. Tissue Antigens 2004;64:281-5.
26. Hong W, Fu Y, Chen S, Wang F, Ren X, Xu A. Distributions of HLA class I alleles and haplotypes in Northern Han Chinese. Tissue Antigens 2005;66:297-304.
27. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Tissue Antigens 2005;65:437-47.
28. Inoue T, Ogawa A, Tokunaga K, et al. Diversity of HLA-B17 alleles and haplotypes in East Asians and a novel Cw6 allele (Cw 0604) associated with B 5701. Tissue Antigens 1999;53:534-44.
29. Shankarkumar U, Sridharan B, Pitchappan RM. HLA diversity among Nadars, a primitive Dravidian caste of South India. Tissue Antigens 2003;62:542-7.
30. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B 5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101:4180-5.
31. Radak Z, Zhao Z, Goto S, Koltai E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Mol Aspects Med 2011;32:305-15.
32. Chen CH, Sun L, Mochly-Rosen D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc Res 2010;88:51-7.
33. Charneira C, Godinho AL, Oliveira MC, et al. Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity. Chem Res Toxicol 2011;24:2129-41.
34. Norcross MA, Luo S, Lu L, et al. Abacavir induces loading of novel self-peptides into HLA-B 57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 2012;26:F21-9.
35. Adam J, Eriksson KK, Schnyder B, Fontana S, Pichler WJ, Yerly D. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol 2012;42:1706-16.
36. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2.
37. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-11.
38. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43:99-102.
39. Lai-Goldman M, Faruki H. Abacavir hypersensitivity: a model system for pharmacogenetic test adoption. Genet Med 2008;10:874-8.
40. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from http://aidsinfo.nih.gov/ contentfiles/lvguidelines/ AdultandAdolescentGL.pdf. Accessed May 12, 2012.
41. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608.
42. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49:651-81.
43. Becquemont L, Alfirevic A, Amstutz U, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011;12:113-24.
44. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte- an update of guidelines. Clin Pharmacol Ther 2011;89:662-73.
45. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/ lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55:49-57.
46. Squires KE, Young B, DeJesus E, et al. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir- boosted atazanavir in HIV-infected patients. HIV Clin Trials 2010;11:69-79.
47. Martin AM, Nolan D, Mallal S. HLA-B 5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens 2005;65:571-4.
48. Hammond E, Mamotte C, Nolan D, Mallal S. HLA-B 5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens 2007;70:58-61.
49. Hammond E, Almeida CA, Mamotte C, et al. External quality assessment of HLA-B 5701 reporting: an international multicentre survey. Antivir Ther 2007;12:1027-32.
50. Colombo S, Rauch A, Rotger M, et al. The HCP5 singlenucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008;198:864-7.
51. Rodriguez-Novoa S, Cuenca L, Morello J, et al. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B 5701. J Antimicrob Chemother 2010;65:1567-9.
52. Sanchez-Giron F, Villegas-Torres B, Jaramillo-Villafuerte K, et al. Association of the genetic marker for abacavir hypersensitivity HLA-B 5701 with HCP5 rs2395029 in Mexican Mestizos. Pharmacogenomics 2011;12:809-14.
53. Badulli C, Sestini R, Sbarsi I, et al. Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B 57:01 typing for eligibility to abacavir treatment in the Italian population. Pharmacogenomics 2012;13:247-9.
54. Ong FS, Deignan JL, Kuo JZ, et al. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics 2012;13:465-75.
55. Grossman I. Routine pharmacogenetic testing in clinical practice: dream or reality? Pharmacogenomics 2007;8:1449-59.
56. Eriksson N, Wadelius M. Prediction of warfarin dose: why, when and how? Pharmacogenomics 2012;13:429-40.